Hydrosoluble medicated nail lacquers: In vitro drug permeation and corresponding antimycotic activity

British Journal of Dermatology

Volumn 162, Issue 2, 2010, Pages 311-317

  Monti, D ^a   Saccomani, L ^a   Chetoni, P ^a   Burgalassi, S ^a   Senesi, S ^a   Ghelardi, E ^a   Mailland, F ^b  

^a UNIVERSITY OF PISA   (Italy)

^b Polichem SA   (Switzerland)

Author keywords

Amorolfine; Bovine hoof membranes; Ciclopirox; In vitroantifungal activity; Transungual permeation; Water soluble nail lacquers

Indexed keywords

AMOROLFINE; CICLOPIROX; NAIL LACQUER; PAINT; POLYMER; TOPICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; DRUG PENETRATION; DRUG SENSITIVITY; FUNGAL STRAIN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NAIL BED; NONHUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL;

ABSORPTION; ADMINISTRATION, TOPICAL; ANIMALS; ANTIFUNGAL AGENTS; CATTLE; HOOF AND CLAW; HUMANS; LACQUER; MORPHOLINES; NAILS; ONYCHOMYCOSIS; PERMEABILITY; PHARMACEUTICAL SOLUTIONS; PYRIDONES; REGRESSION ANALYSIS; SOLUBILITY; VEHICLES;

EID: 74349129231     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09504.x     Document Type: Article

References (22)

1. Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999 141 (Suppl. 56 1 4.
2. Cribier BJ, Bakshi RB. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with nondermatophyte infections. Br J Dermatol 2004 150 : 414 420.
3. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005 19 : 21 9.
4. Evans EGV. The rationale for combination therapy. Br J Dermatol 2001 145 (Suppl. 60 9 13.
5. Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002 236 : 1 26.
6. McKay DA, Schofield OM, Benton EC. Terbinafine-induced subacute lupus erythematosus. Acta Derm Venereol (Stockh) 2004 84 : 472 474.
7. Gupta AK. Ciclopirox topical solution 8% combined with oral terbinafine to treat onychomycosis: a randomized evaluator-blinded study. J Drugs Dermatol 2005 4 : 481 485.
8. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol 2001 145 (Suppl. 60 15 19.
9. Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007 20 : 31 46.
10. Hay RJ. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001 145 (Suppl. 60 3 8.
11. Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 2003 149 : 296 305.
12. Monti D, Saccomani L, Chetoni P et al. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm 2005 31 : 11 17.
13. Mertin D, Lippold BC. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: influence of the partition coefficient octanol/water and the water solubility of drugs on their permeability and maximum flux. J Pharm Pharmacol 1997 49 : 30 4.
14. Mertin D, Lippold BC. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: penetration of chloramphenicol from lipophilic vehicles and a nail lacquer. J Pharm Pharmacol 1997 49 : 241 245. (Pubitemid 27197006)
15. Mertin D, Lippold BC. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efficacy. J Pharm Pharmacol 1997 49 : 866 872. (Pubitemid 27424864)
16. Baker S, Sanders V, Hold K, Plattner J. In vitro nail penetration of AN2690, effect of vehicle, and coefficient of efficacy. J Am Acad Dermatol 2007 56 : AB124.
17. Zar JH. Biostatistical Analysis, 2nd edn. Englewood Cliffs, NJ : Prentice Hall, 1984.
18. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast; Approved Standard, 2nd edn. CLSI Document M27-A2. Wayne, PA : CLSI, 2002.
19. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, 2nd edn. CLSI Document M38-A. Wayne, PA : CLSI, 2002.
20. Baden HP, Goldsmith LA, Fleming B. A comparative study of the physicochemical properties of human keratinized tissues. Biochim Biophys Acta 1973 322 : 269 278.
21. Baden HP, Kubilus J. Fibrous proteins of bovine hoof. J Invest Dermatol 1983 81 : 220 224.
22. Neubert RH, Gensbügel C, Jäckel A, Wartewig S. Different physicochemical properties of antimycotic agents are relevant for penetration into and through human nails. Pharmazie 2006 61 : 604 607.